Description
CC-671 is a dual TTK/CLK2 inhibitor. It acts by inhibiting the phosphorylation of KNL1 and SRp75, direct substrates of TTK and CLK2. It is a monotherapy candidate for treatment of triple negative breast cancer.
Product Unit Size | Cost | Quantity | Stock |
---|
CC-671 is a dual TTK/CLK2 inhibitor. It acts by inhibiting the phosphorylation of KNL1 and SRp75, direct substrates of TTK and CLK2. It is a monotherapy candidate for treatment of triple negative breast cancer.
Cas No. | 1618658-88-0 |
---|---|
Purity | ≥98% |
Formula | C28H28N6O4 |
Formula Wt. | 512.57 |
IUPAC Name | 4-{[4-(Cyclopentyloxy)-5-(2-methyl-1,3-benzoxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-3-methoxy-N-methylbenzamide |
Synonym | CC 671, CC671 |
Store Temp | -20°C |
---|---|
Ship Temp | Ambient |
MSDS | |
---|---|
Info Sheet |
Riggs J., Nagy M., et al. The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen. J Med Chem. 60(21):8989-9002 (2017). PMID: 28991472.
Zhu D., Xu S., et al. Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1-S Checkpoint. Mol Cancer Ther. 17(8):1727-38 (2018). PMID: 29866747.
Non-opioid analgesic.
Endogenous tripeptide, involved in HPA signalin...
Synthetic ITC.
β2-adrenergic agonist.
ATP-sensitive K+ channel blocker, potential RyR...
p53 activator, IMPDH and SIRT1 inhibitor.
STING antagonist
Isoflavonoid found in Glycyrrhiza; GABA-A posit...
NSAID; COX-1/2 inhibitor.
Steroid found in myrrh; FXR antagonist.
Heterocyclic light-emitting compound, natural l...
Butyrophenone; σ2 agonist, α1-adrenergic, D2,...
ALK and IGF-1R inhibitor.
mTOR inhibitor.
Viral neuraminidase inhibitor, potential MAO-A ...
CB2 receptor antagonist.
Bufanolide steroid found in Bufo arenarum;VEGFR...
Cyclic peptide; calcineurin inhibitor.
Calcium channel blocker.
Purine derivative; CDK inhibitor.